Navigation Links
Jeffrey Wasserstein Joins Greenhill as Managing Director Focused on the Pharmaceutical Sector
Date:9/10/2012

NEW YORK, Sept. 10, 2012 /PRNewswire/ -- Greenhill & Co., Inc. (NYSE: GHL), a leading independent investment bank, announced today that Jeffrey Wasserstein has joined the Firm in New York to enhance its focus on the pharmaceutical sector.

Mr. Wasserstein has a 20 year history in the pharmaceutical industry in corporate development and commercial operating roles for a series of pharmaceutical companies.  Most recently he served as Senior Vice President of Business Development & Strategy at Fougera Pharmaceuticals, which was recently sold to the Sandoz division of Novartis AG.  Prior to his time at Fougera he spent five years at Dr. Reddy's Laboratories, a leading global generic pharmaceutical company, as founder and President of a branded specialty pharmaceutical subsidiary focused on dermatology as well as the Executive Vice President of North America and a member of Dr. Reddy's Global Management Council.  He began his career in the sector at Schering-Plough Corporation, where he started in a legal role and rose to first head of Corporate Business Development, then President of Schering Canada and later Senior Vice President of the parent company.  Prior to his time at Schering-Plough, he was an attorney at Wachtell, Lipton, Rosen & Katz for six years, focused on mergers and acquisitions advice.

Scott L. Bok, Chief Executive Officer of Greenhill, said, "The health care sector has become a very important part of our business, as an increasing number of companies in health care services, health care devices and pharmaceuticals have opted for our unconflicted, client-focused approach to advising clients on important transactions.  With the addition of Jeff we are significantly increasing our knowledge of the trends and opportunities in the pharmaceutical sector, as well as our access to a much larger range of companies in that sector."

Jeffrey Wasserstein said, "I am very pleased to be joining Greenhill, where I have known some of its partners for many years.  In my new role I can build upon my many relationships in the industry as well as my significant experience as a corporate development and operating executive and as an external advisor.  I look forward to utilizing my deep industry knowledge, an insider's appreciation for the many challenges facing the senior management and boards of companies in the pharmaceutical sector and my significant transaction experience to advise pharmaceutical companies on important transactions and other matters."

Greenhill & Co., Inc. is a leading independent investment bank focused on providing financial advice on significant mergers, acquisitions, restructurings, financings and capital raising to corporations, partnerships, institutions and governments.  It acts for clients located throughout the world from its offices in New York, London, Frankfurt, Stockholm, Sydney, Tokyo, Toronto, Chicago, Dallas, Houston, Los Angeles, Melbourne and San Francisco.

Contact:
Christopher T. Grubb
Chief Financial Officer
Greenhill & Co., Inc.
(212) 389-1800


'/>"/>
SOURCE Greenhill & Co., Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. AgaMatrix elects Jeffrey B. Kindler to its Board of Directors
2. Financier Jeffrey Epstein And Mount Sinai Hospital Support 3D Mammograms For Breast Cancer
3. Jeffrey Modell Foundation Opens Diagnostic Center for Primary Immunodeficiencies at Midwest Immunology Clinic
4. The Largest Private Funder Of Melanoma Research Receives Vital Support From Activist Jeffrey Epstein
5. Gerald E. Quirk Joins Choate, Hall & Stewart LLP as Co-Chair of Life Sciences Group
6. Dr. Magnus Persson Joins Cerecors Board of Directors
7. Joseph Rogers Joins SRI International as Executive Director of New Health Sciences Section in Biosciences Division
8. Pharmacy Industry Veteran Joins Millennium Pharmacy Systems as SVP Operations
9. Biotechnology Thought Leader, Dr. Abbie Celniker, Joins ImaginAb Board of Directors as Chairman
10. Dr. Gerald Yakatan Joins Imprimis Pharmaceuticals Science and Regulatory Advisory Board
11. MinuteClinic Joins with American Heart Association to Help Americans Reduce High Blood Pressure
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/8/2016)... AMSTERDAM , December 8, 2016 Information ... TM metrics in Scopus , the world,s largest ... free access to comprehensive metrics for journals from over 5,000 publishers. ... publish, which journals to subscribe to and when to adjust a ... , , ...
(Date:12/8/2016)... 2016 According to the research report, ... is expected to be worth US$9.7 bn by the ... Between the forecast years of 2016 and 2024, the global ... The leading players operating in the global diabetes injection pens ... plc., Biocon Ltd., and Sanofi S.A. Transparency Market Research reports ...
(Date:12/8/2016)... 2016 According to a new market research report ... Therapeutic (Pain, Insulin)), End Use (Sports, Fitness, RPM), Type (Smart watch, Patch), ... global market, in terms of value, is projected to reach 12.14 Billion ... 18.0% during the forecast period. Continue Reading ... ...
Breaking Medicine Technology:
(Date:12/8/2016)... ... 2016 , ... David J. Dykeman , Ginger Pigott , and ... speak at DeviceTalks West, Dec. 12, 2016, at the Fairmont Newport Beach in California. ... firm’s global Life Sciences & Medical Technology Group have been featured speakers at every ...
(Date:12/8/2016)... Tampa, Fla (PRWEB) , ... December 08, 2016 ... ... offering smarter modes of access for customers and employees that are both engaging ... ChangeGear 7 with Service Smart Technology, the software company revealed today its plans ...
(Date:12/8/2016)... ... 2016 , ... Catalent Pharma Solutions, the leading global provider ... products, today announced that it had joined the Pharmaceutical Supply Chain Initiative (PSCI). ... unite pharmaceutical and healthcare companies that share a vision of better, social, environmental ...
(Date:12/8/2016)... ... December 08, 2016 , ... STAT courier is pleased ... a convenient service for Texas, they are expanding their presence in Dallas. One of ... spree that will bring new jobs to the Dallas and Forth Worth market. STAT ...
(Date:12/8/2016)... ... December 08, 2016 , ... Today’s patients are encouraged to ... mind, SIGVARIS has created a new line of anti-embolism stockings to help prevent ... the benefits of graduated compression when transitioning from recovery to early rehabilitation. , ...
Breaking Medicine News(10 mins):